Avalyn Pharma bolsters balance sheet with $345 million IPO, projects runway into 2029

Avalyn Pharma (NASDAQ:AVLN) provided a comprehensive update on its financial position and clinical development programs for the first quarter of 2026, underscored by a strengthened capital base following its recent initial public offering.

The company concluded the quarter with $123.1 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

This figure notably excludes the proceeds from its upsized initial public offering, which generated gross proceeds of $345 million.

With this influx of capital, Avalyn management projects that its current liquidity is sufficient to fund its clinical operations and research initiatives through 2029.

Avalyn’s research and development efforts continue to center on its portfolio of inhaled antifibrotic treatments designed for rare respiratory conditions.

The company’s lead candidate, AP01, remains in the Phase 2b MIST trial for progressive pulmonary fibrosis, with enrollment on track to conclude by mid-2026.

Parallel development continues for the AP02 program, an inhaled therapy for idiopathic pulmonary fibrosis.

The Phase 2 AURA trial for AP02 is currently enrolling patients, with topline data anticipated in 2027.

Looking toward the end of the year, the company plans to initiate a Phase 1 trial for its AP03 combination therapy.

The successful completion of the upsized IPO serves as a foundational element for the company’s current operational strategy, allowing for the concurrent advancement of these late-stage respiratory assets while mitigating near-term financing requirements.